Form 8-K - Current report:
SEC Accession No. 0001087294-25-000017
Filing Date
2025-11-04
Accepted
2025-11-04 17:11:16
Documents
14
Period of Report
2025-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20251104.htm   iXBRL 8-K 28508
2 EX-99.1 a2025q3-ex991er.htm EX-99.1 252848
6 image_0.jpg GRAPHIC 18991
  Complete submission text file 0001087294-25-000017.txt   449681

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20251104.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20251104_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20251104_pre.xml EX-101.PRE 12611
16 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20251104_htm.xml XML 3015
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 251450649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)